Plain-English translation of NCT06886074 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether blinatumomab, an immunotherapy medication, can effectively erase tiny amounts of leukemia that sometimes remain even after standard chemotherapy has put the cancer into remission. The treatment is given as a continuous infusion through an IV over 7 days, and researchers will check whether this medication successfully clears the remaining cancer cells.
Even when leukemia appears to be gone after chemotherapy, sometimes a small number of cancer cells remain that are too few to detect with regular tests. These leftover cells can cause the cancer to return, so researchers are testing this medication to see if a short course can eliminate them completely before a bone marrow transplant.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as a continuous 24-hour IV infusion for 7 days, starting with lower doses and gradually increasing. You would be hospitalized for the first day, then discharged home with follow-up visits. On day 10, you would return for a bone marrow test to check whether the remaining cancer cells have been eliminated, with results and further care planning discussed on day 14.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Mexico